Back to results
US 11,726,100 B2Granted
Method of treating large vessel occlusion stroke
AssigneePockit Diagnostics Limited
InventorsEdoardo Gaude, Gonzalo Ladreda Mochales, Marcos Ladreda Mochales
Life of this patent
Estimating the term…
Abstract
The invention relates to the diagnosis of stroke resulting from occlusion of one or more large vessels in the brain, and in particular to the diagnosis of stroke resulting from occlusion of one or more large vessels in the brain using one or more biomarkers.
Claims13
A method of treating large vessel occlusion (LVO) stroke comprising:
- (i) identifying an individual presenting with stroke symptoms;
- (ii) determining that the individual is experiencing LVO stroke comprising:
- (a) within 24 hours of step (i), obtaining a blood sample from the individual;
- (b) measuring the amount of D-dimer in the blood sample, or in plasma or serum derived therefrom;
- and
- (c) measuring the amount of glial fibrillary acidic protein (GFAP) in the blood sample, or in plasma or serum derived therefrom;
- (iii) providing LVO therapy to the individual having elevated levels of D-dimer and decreased levels of GFAP compared to levels of D-dimer and GFAP in one or more controls, wherein the individual receiving LVO therapy has D-dimer levels of at least 0.5 μg/ml and GFAP levels of less than 265 pg/ml.
4 more elements
A method of treating large vessel occlusion (LVO) stroke comprising:
- (i) identifying an individual presenting with stroke symptoms;
- (ii) determining that the individual is experiencing LVO stroke comprising:
- (a) within 24 hours of step (i), obtaining a blood sample from the individual;
- (b) measuring the amount of D-dimer in the blood sample, or in plasma or serum derived therefrom;
- (c) measuring the amount of glial fibrillary acidic protein (GFAP) in the blood sample, or in plasma or serum derived therefrom;
- and
- (d) measuring one or more of (1) the amount of osteopontin (OPN) in the sample and (2) the amount of osteoprotegerin (OPG) in the blood sample, or in plasma or serum derived therefrom;
- and
- (iii) providing LVO therapy to the individual having elevated levels of D-dimer, decreased levels of GFAP, and one or more of (1) elevated levels of OPN and (2) elevated levels of OPG, compared to levels of D-dimer, GFAP, and OPN and/or OPG in one or more controls.
6 more elements
Dependencies are inferred from the claim text.